ArticleeLife2022
Colicin E1 opens its hinge to plug TolC.
Article in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Metagenomic screening of antimicrobial peptide candidates and isolation of two active peptides from bat gut bacteria.World journal of microbiology & biotechnology · 2026Article
- Computational and Structure-Guided engineering of colicin E1 and E2 for EMT -driven cadherin selectivity in cancer.Journal, genetic engineering & biotechnology · 2026Article
- The Role of Selected Bacteria in Breast Cancer Initiation and Development.International journal of molecular sciences · 2026Review
- Bacteriocin biophysics: From protein-protein interaction models to navigators of the bacterial cell envelope.The Journal of biological chemistry · 2026Article
- Purification and Sonication-Assisted Cryo-EM Grid Preparation of TolC.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Targeting the AcrAB-TolC efflux pump by small molecules selectively addressing the outer membrane factor TolC.Frontiers in pharmacology · 2026Article
- A public resource of 15 genomically characterized representative strains ofMicrobial genomics · 2026Article
- Development of a nonreplicative phage-based DNA delivery system and its application to antimicrobial therapies.PNAS nexus · 2025Article
- A robust protocol for refolding TolC and other outer membrane components of tripartite efflux pumps from inclusion bodies.Methods in enzymology · 2025Article
- Use of zebrafish to identify host responses specific to type VI secretion system mediated interbacterial antagonism.PLoS pathogens · 2024Article
- Story of Pore-Forming Proteins from Deadly Disease-Causing Agents to Modern Applications with Evolutionary Significance.Molecular biotechnology · 2024Review
- Extending the Potency and Lifespan of Antibiotics: Inhibitors of Gram-Negative Bacterial Efflux Pumps.ACS infectious diseases · 2024Review
- Cryo-electron microscopy-based drug design.Frontiers in molecular biosciences · 2024Review
- Enhanced Antibacterial Activity of Novel Fluorescent Glutathione-Capped Ag Nanoclusters.International journal of molecular sciences · 2023Article
- Detergent headgroups control TolC folding in vitro.Biophysical journal · 2023Article
- A coevolution experiment betweenMicrobiology (Reading, England) · 2023Article
- Microcins reveal natural mechanisms of bacterial manipulation to inform therapeutic development.Microbiology (Reading, England) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
Abstract
The double membrane architecture of Gram-negative bacteria forms a barrier that is impermeable to most extracellular threats. Bacteriocin proteins evolved to exploit the accessible, surface-exposed proteins embedded in the outer membrane to deliver cytotoxic cargo. Colicin E1 is a bacteriocin produced by, and lethal to,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.